Is RYTM or SER more undervalued in 2026?

CirclFi compares Rhythm Pharmaceuticals, Inc. (RYTM) and Serina Therapeutics, Inc. (SER) using 13 institutional-grade valuation models. RYTM has a Quality of Company score of 6.1/10 while SER scores 4.9/10.

Which is a better buy — RYTM or SER?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RYTM and SER valuations compare?

RYTM at $92.98 and SER at $1.95 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RYTM vs SER Valuation Comparison 2026 — Intrinsic Value Analysis

RYTM

Biotechnology

Rhythm Pharmaceuticals, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$92.98

Last close

Models

12/13

Active

SER

Biotechnology

Serina Therapeutics, Inc.

Quality

4.9

out of 10

Value Trap

LOW

Price

$1.95

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	RYTM Fair Value	RYTM Upside	SER Fair Value	SER Upside
Bayesian DCF	Intrinsic	$26.90	-71.1%	$1.20	-38.7%
Earnings Power Value	Intrinsic	$3.54	-95.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.57	-97.2%	$2.49	+27.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RYTM vs SER — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RYTM vs SER — Which Stock Is More Undervalued?

RYTM scores higher with a 6.1/10 quality rating vs SER's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rhythm Pharmaceuticals, Inc. (RYTM) and Serina Therapeutics, Inc. (SER) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RYTM currently trades at $92.98 with a QOC of 6.1/10, while SER trades at $1.95 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).